Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Treatments: Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Methotrexate; Vincristine

Criteria

Inclusion Criteria:

• Subject must be previously untreated, except for steroids.

• Subject must be less than or equal to 18 years of age.

• Subject must have a histologic diagnosis of small noncleaved cell (SNCC) NHL or large cell NHL (B-cell), or B-cell acute lymphocytic leukemia.

Exclusion Criteria:

• Previously treated disease